Benzinga | Apr 14, 2021 06:11AM EDT

SVB Leerink Initiates Coverage On Global Blood Therapeutics with Outperform Rating, Announces Price Target of $54

SVB Leerink analyst Andrew Berens initiates coverage on Global Blood Therapeutics (NASDAQ:GBT) with a Outperform rating and announces Price Target of $54.